Targeting telomerase with radiolabeled inhibitors

Waghorn, P. A., Jackson, M. R. , Gouverneur, V. and Vallis, K. A. (2017) Targeting telomerase with radiolabeled inhibitors. European Journal of Medicinal Chemistry, 125, pp. 117-129. (doi: 10.1016/j.ejmech.2016.09.028) (PMID:27657809) (PMCID:PMC5154340)

194400.pdf - Published Version
Available under License Creative Commons Attribution.



The expression of telomerase in approximately 85% of cancers and its absence in the majority of normal cells makes it an attractive target for cancer therapy. However the lag period between initiation of telomerase inhibition and growth arrest makes direct inhibition alone an insufficient method of treatment. However, telomerase inhibition has been shown to enhance cancer cell radiosensitivity. To investigate the strategy of simultaneously inhibiting telomerase while delivering targeted radionuclide therapy to cancer cells, 123I-radiolabeled inhibitors of telomerase were synthesized and their effects on cancer cell survival studied. An 123I-labeled analogue of the telomerase inhibitor MST-312 inhibited telomerase with an IC50 of 1.58 μM (MST-312 IC50: 0.23 μM). Clonogenic assays showed a dose dependant effect of 123I-MST-312 on cell survival in a telomerase positive cell line, MDA-MB-435.

Item Type:Articles
Additional Information:This work was supported by Cancer Research UK (C5255/A15935) and the Medical Research Council (MC_PC_12004).
Glasgow Author(s) Enlighten ID:Jackson, Dr Mark
Authors: Waghorn, P. A., Jackson, M. R., Gouverneur, V., and Vallis, K. A.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:European Journal of Medicinal Chemistry
ISSN (Online):1768-3254
Published Online:10 September 2016
Copyright Holders:Copyright © 2016 The Authors
First Published:First published in European Journal of Medicinal Chemistry 125:117-129
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record